About Us

Paul Gineste is the Chief Executive Officer of SpikImm, bringing over 30 years of industry experience and a strong track record in executive leadership and clinical development. In his previous role, he led the clinical development of obefazimod, Abivax’s lead asset (ABVX.PA), from first-in-human studies through Phase 3. He also played a key role in securing more than $500 million in equity and debt financings, supporting Abivax’s growth from seed stage to IPOs. Paul holds a PharmD from the University of Rouen and an LL.M. from the University of Paris.

Catherine has over 30 years' experience in leading the translational development of biological entities, overseeing strategy and all R&D operations (including IP, Research, Pre-clinical, CMC, Regulatory, bioanalytical, clinical and market access). She has successfully taken several products from hit selection to Phase I/II POC (e.g ublituximab now approved in the US), obtained 2 Temporary Use Authorizations and prepared a pre-BLA fast-track. She began her career in clinical research at Pierre Fabre and headed Chiltern (now Covance)'s clinical department for many years. In 2002, she moved into full drug development as R&D Program Director for LFB Biotech and since 2014, she has been CDO or COO in several start-ups while advising VCs and public institutions. She has been also a Board member of Ysopia for 4 years. Catherine is a Doctor of Pharmacy, PMBook certified and completed her training in business and strategy at Essec. She is the Chief Development Officer of SpikImm.

Karine Lacombe, M.D, PhD, is an infectious diseases specialist whose clinical practice, teaching and research are focusing on viral infections. Dr Lacombe grew in the French Alps where she completed her undergraduate studies at Grenoble Science University (Université Joseph Fourier). She graduated from Pierre et Marie Curie Medical University in Paris and completed her residency in St Antoine Hospital, Paris and St André Hospital, Bordeaux. In 2006, she got her PhD in Epidemiology on HIV / hepatitis B coinfection and the determinants of liver fibrosis. She became an associate Professor in Infectious Diseases in 2007 and got a full professorship position at Sorbonne Universite in 2016. Recent publications include results of phase 2 and 3 clinical trials in HIV, chronic hepatitis as well as respiratory viral infections. She is one of the international leaders in chronic viral infections and has been giving plenary lectures in all international conferences in infectious diseases. Since March 2020, she has been deeply involved as a clinician and researcher but also at a political level in the management of the Covid-19 crisis. As a specialist in epidemiology and methodology of phase 1 to 3 clinical trials, she has been involved in the development of numerous innovative drugs for clinical stage - biochtech companies such as Spikimm or Evexta-Bio. She is the head of the Infectious Diseases Department in St Antoine Hospital, AP-HP, Paris, and supervises the clinical research commission of the Board of Physicians of AP-HP.

Vincent Dagommer is the CFO of SpikImm. He has spent most of his career in the pharmaceutical industry, including 15 years in Brazil, Switzerland and Belgium. He worked in large multinationals (Eli Lilly, Bayer, Novartis) and then at Guerbet, a leading mid-sized company in medical imaging. After 15 years in controlling positions, he moved to BD&L at Novartis in 2011. From 2010 to 2014, he was a member of the Board of Directors of Guerbet, where he became Chairman of the Audit Committee. He moved into operations at Guerbet at the end of 2013, taking over executive positions in country management (Belgium, France), post-acquisition integration, and group transformation. He joined Truffle Capital in February 2022 as Operating Partner where he currently leads a shared service team providing support in finance, HR, legal and general services to several portfolio companies in MedTech and Biotech. Vincent graduated from ESCP